A Phase 3 interventional study of Idelalisib in Follicular Lymphoma, sponsored by Gilead Sciences. Terminated at 66 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.
Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 9th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3
First in 2011; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 6 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
17 studies in Lymphoma, Follicular by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 9 (69%) have results posted.
Among the 17 studies in Lymphoma, Follicular by Gilead Sciences, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 3, and was the 14th registered.
Gilead Sciences’s Lymphoma, Follicular studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing idelalisib in Lymphoma, Follicular, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 17 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive idelalisib 150 mg twice daily continuously. For participants enrolled prior to protocol amendment 5: Based on the independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily.
Drug: Idelalisib
Participants will receive idelalisib 100 mg twice daily continuously. Based on the IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily. As of protocol amendment 5, enrollment to this arm has been closed.
Drug: Idelalisib
Participants will receive idelalisib 150 mg twice daily in 28-day cycles with 21 days on-treatment and 7 days off-treatment.
Drug: Idelalisib
Idelalisib tablet administered orally
Also known as: Zydelig®, GS-1101, CAL-101
Overall Response Rate (ORR)
ORR was defined as percentage of participants who achieve a partial response (PR) or complete response (CR). PR criteria: No evidence of new disease, a ≥50% decrease from baseline in sum of products of diameters (SPD) of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. Persistence of bone marrow involvement in a participant who meets other criteria for CR based on the disappearance of all nodal and extra-nodal masses. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in longest dimension (LD) for large nodes and ≤1.0 cm in LD, ≤1.0 cm in longest perpendicular dimension (LPD) for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.
Time frame: Randomization up to end of treatment (maximum duration: 73.5 months)
Number of Participants With Grade 4 or Higher Treatment-Emergent Adverse Events (TEAEs)
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.
Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)
Duration of Response (DOR)
DOR: interval from first documentation of CR/PR to earlier of first documentation of disease progression (PD) by independent review committee (IRC)/death from any cause. PR:No evidence of new disease,≥50% decrease from baseline in SPD of index lesions,no increase in non-index disease, no increase in liver/spleen size,no new liver/spleen enlargement; Persistence of bone marrow involvement in participant who meets other CR criteria. CR: No evidence of new disease,regression of all index nodal lesions to normal size (large nodes:≤1.5 cm in LD;small nodes:≤1.0 cm in LD,≤1.0 cm in LPD), regression to normal of all nodal non-index disease,disappearance of all detectable extra-nodal index,non-index disease,normal spleen and liver size, no new liver/spleen enlargement; PD: New node of \>1.5 cm or \>1.0 to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion,new non-index disease,increase by 50% in SPD of index lesions,LD of individual node/extra-nodal mass.
Time frame: From first documentation of CR or PR until PD or death from any cause (maximum duration: 73.5 months)
Overall Response Rate (ORR) by Week 24
ORR by Week 24 is defined as the percentage of participants who achieve a PR or CR by Week 24. PR criteria: No evidence of new disease, a 50% decrease from baseline in SPD of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in LD for large nodes and ≤1.0 cm in LD, ≤1.0 cm in LPD for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.
Time frame: First dose date up to Week 24
Number of Participants With Any TEAE, Grade 3 or Higher TEAEs, Serious TEAEs, Idelalisib-related TEAEs, TEAEs Leading to Interruption or Discontinuation of Idelalisib
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants are counted at the highest AE grade experienced.
Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)
Number of Participants With Clinically Significant Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days. Laboratory abnormalities included hematology and serum chemistry parameters. Clinically significant laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for severity as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening). The number of participants with any post-baseline abnormal laboratory value in Grade 1-4 categories are reported.
Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)
Time to Onset of Adverse Events of Interest (AEIs)
Time to onset of AEIs is defined as the interval (in months) from the start of idelalisib treatment to the first documentation of start of AEI. AEIs included grade ≥ 3 diarrhea/colitis, rash, febrile neutropenia, infection, and any grade of: Pneumonitis, bowel perforation, progressive multifocal leukoencephalopathy (PML), Pneumocystis jirovecii pneumonia (PJP), cytomegalovirus (CMV) infection, and organizing pneumonia.
Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)
Progression-Free Survival (PFS)
PFS is defined as the interval (in months) from randomization to the earlier of the first documentation of PD by IRC or death from any cause. PD criteria: New node of \>1.5 cm or \>1.0 cm to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion, new non-index disease, increase by 50% in SPD of index lesions, LD of individual node/extra-nodal mass.
Time frame: Randomization up to PD or death from any cause (maximum duration: 73.5 months)
Overall Survival (OS)
OS is defined as the interval (in months) from randomization to death from any cause.
Time frame: Randomization up to death from any cause (maximum duration: 73.5 months)
Trough Plasma Concentration of Idelalisib
Time frame: Predose on Day 1, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 32, and 48
Peak Plasma Concentration of Idelalisib
Time frame: 1.5 hours postdose on Day 1, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 32, and 48
Participants were enrolled at study sites in Australia, Canada, Europe, Israel, and the United Kingdom.
| Milestone | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Started | 47 | 27 | 22 |
| Completed | 0 | 0 | 0 |
| Not completed | 47 | 27 | 22 |
| Withdrew: Investigator's discretion | 17 | 11 | 2 |
| Withdrew: Progressive disease | 11 | 7 | 6 |
| Withdrew: Study terminated by sponsor | 6 | 4 | 7 |
| Withdrew: Death | 7 | 0 | 5 |
| Withdrew: Withdrew consent | 4 | 2 | 0 |
| Withdrew: Initiation of non-study specific anti-cancer therapy in the absence of progression | 1 | 2 | 1 |
| Withdrew: Enrolled but never treated | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
ORR was defined as percentage of participants who achieve a partial response (PR) or complete response (CR). PR criteria: No evidence of new disease, a ≥50% decrease from baseline in sum of products of diameters (SPD) of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. Persistence of bone marrow involvement in a participant who meets other criteria for CR based on the disappearance of all nodal and extra-nodal masses. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in longest dimension (LD) for large nodes and ≤1.0 cm in LD, ≤1.0 cm in longest perpendicular dimension (LPD) for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.
| percentage of participants | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Overall Response Rate (ORR) | 38.3 (24.5 to 53.6) | 44.4 (25.5 to 64.7) | 40.9 (20.7 to 63.6) |
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.
| Participants | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Number of Participants With Grade 4 or Higher Treatment-Emergent Adverse Events (TEAEs) | 15 | 12 | 8 |
DOR: interval from first documentation of CR/PR to earlier of first documentation of disease progression (PD) by independent review committee (IRC)/death from any cause. PR:No evidence of new disease,≥50% decrease from baseline in SPD of index lesions,no increase in non-index disease, no increase in liver/spleen size,no new liver/spleen enlargement; Persistence of bone marrow involvement in participant who meets other CR criteria. CR: No evidence of new disease,regression of all index nodal lesions to normal size (large nodes:≤1.5 cm in LD;small nodes:≤1.0 cm in LD,≤1.0 cm in LPD), regression to normal of all nodal non-index disease,disappearance of all detectable extra-nodal index,non-index disease,normal spleen and liver size, no new liver/spleen enlargement; PD: New node of \>1.5 cm or \>1.0 to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion,new non-index disease,increase by 50% in SPD of index lesions,LD of individual node/extra-nodal mass.
| months | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Duration of Response (DOR) | 27.1 (7.7 to NA) | 18.0 (2.7 to NA) | 5.7 (0.3 to NA) |
ORR by Week 24 is defined as the percentage of participants who achieve a PR or CR by Week 24. PR criteria: No evidence of new disease, a 50% decrease from baseline in SPD of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in LD for large nodes and ≤1.0 cm in LD, ≤1.0 cm in LPD for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.
| percentage of participants | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Overall Response Rate (ORR) by Week 24 | 36.2 (22.7 to 51.5) | 33.3 (16.5 to 54.0) | 27.3 (10.7 to 50.2) |
TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants are counted at the highest AE grade experienced.
| Participants | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Any TEAE | 45 | 26 | 19 |
| Grade 3 or Higher TEAEs | 41 | 25 | 12 |
| Serious TEAEs | 31 | 19 | 11 |
| Idelalisib-related TEAEs | 38 | 25 | 11 |
| TEAEs Leading to Interruption of Idelalisib | 32 | 18 | 6 |
| TEAEs Leading to Discontinuation of Idelalisib | 28 | 13 | 4 |
Treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days. Laboratory abnormalities included hematology and serum chemistry parameters. Clinically significant laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for severity as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening). The number of participants with any post-baseline abnormal laboratory value in Grade 1-4 categories are reported.
| Participants | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Hematology: Grade 1 | 7 | 5 | 2 |
| Hematology: Grade 2 | 12 | 7 | 5 |
| Hematology: Grade 3 | 15 | 11 | 5 |
| Hematology: Grade 4 | 6 | 3 | 2 |
| Serum Chemistry: Grade 1 | 9 | 5 | 8 |
| Serum Chemistry: Grade 2 | 17 | 8 | 4 |
| Serum Chemistry: Grade 3 | 10 | 11 | 6 |
| Serum Chemistry: Grade 4 | 7 | 3 | 1 |
Time to onset of AEIs is defined as the interval (in months) from the start of idelalisib treatment to the first documentation of start of AEI. AEIs included grade ≥ 3 diarrhea/colitis, rash, febrile neutropenia, infection, and any grade of: Pneumonitis, bowel perforation, progressive multifocal leukoencephalopathy (PML), Pneumocystis jirovecii pneumonia (PJP), cytomegalovirus (CMV) infection, and organizing pneumonia.
No measurements were reported for this outcome.
PFS is defined as the interval (in months) from randomization to the earlier of the first documentation of PD by IRC or death from any cause. PD criteria: New node of \>1.5 cm or \>1.0 cm to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion, new non-index disease, increase by 50% in SPD of index lesions, LD of individual node/extra-nodal mass.
| months | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Progression-Free Survival (PFS) | 9.8 (5.5 to 28.7) | 19.4 (13.9 to 23.3) | 8.3 (2.9 to 8.7) |
OS is defined as the interval (in months) from randomization to death from any cause.
| months | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Overall Survival (OS) | 28.7 (14.0 to NA) | NA (23.3 to NA) | NA (13.9 to NA) |
| nanograms per milliliter (ng/ml) | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Day 1 | NA ± NA | NA ± NA | NA ± NA |
| Week 2 | 683.68 ± 514.166 | 382.94 ± 352.842 | 636.35 ± 461.042 |
| Week 4 | 623.64 ± 466.557 | 447.78 ± 356.971 | 94.14 ± 231.647 |
| Week 6 | 581.20 ± 470.988 | 361.90 ± 248.996 | 596.80 ± 401.619 |
| Week 8 | 655.16 ± 498.873 | 430.33 ± 477.877 | 77.66 ± 274.313 |
| Week 10 | 616.05 ± 370.862 | 356.12 ± 372.557 | 387.40 ± 314.249 |
| Week 12 | 630.56 ± 664.066 | 389.21 ± 466.104 | 272.44 ± 626.451 |
| Week 16 | 729.23 ± 832.158 | 730.29 ± 936.798 | 111.67 ± 296.666 |
| Week 20 | 525.91 ± 411.330 | 745.58 ± 841.105 | 107.34 ± 269.434 |
| Week 24 | 460.74 ± 321.766 | 728.76 ± 760.391 | NA ± NA |
| Week 32 | 446.13 ± 450.821 | 388.58 ± 351.293 | 352.73 ± 875.923 |
| Week 48 | 706.13 ± 580.022 | 552.13 ± 571.081 | 165.00 ± 368.951 |
| ng/ml | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| Day 1 | 2626.12 ± 1330.290 | 1575.81 ± 803.317 | 2221.35 ± 1621.291 |
| Week 2 | 2306.12 ± 810.433 | 1520.29 ± 675.089 | 2186.89 ± 1265.850 |
| Week 4 | 2353.95 ± 930.754 | 1528.48 ± 759.936 | 2608.12 ± 1009.937 |
| Week 6 | 2433.33 ± 1092.969 | 1682.52 ± 939.455 | 2341.33 ± 948.133 |
| Week 8 | 2207.59 ± 980.606 | 1649.25 ± 940.683 | 2786.43 ± 1591.408 |
| Week 10 | 2435.00 ± 1027.469 | 1601.11 ± 804.605 | 2380.00 ± 1118.679 |
| Week 12 | 2328.13 ± 1141.764 | 1658.89 ± 837.159 | 2316.20 ± 1391.815 |
| Week 16 | 2634.39 ± 1323.611 | 1756.37 ± 826.784 | 2372.50 ± 1335.420 |
| Week 20 | 2354.26 ± 1440.587 | 1925.29 ± 776.516 | 2177.69 ± 1417.505 |
| Week 24 | 2058.47 ± 905.071 | 1914.65 ± 1151.998 | 1906.30 ± 1099.458 |
| Week 32 | 2009.71 ± 1231.296 | 2028.00 ± 593.236 | 1825.00 ± 947.892 |
| Week 48 | 2655.13 ± 1348.957 | 1448.33 ± 650.798 | 1312.00 ± 850.894 |
Collected over All-Cause Mortality: Enrollment up to last follow up visit (maximum 73.5 months); Adverse Events: First dose date up to 30 days after last dose of study drug (maximum 64.6 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib 150 mg BID | 20/47 (42.6%) | 31/47 (66%) | 44/47 (93.6%) |
| Idelalisib 100 mg BID | 12/27 (44.4%) | 19/27 (70.4%) | 24/27 (88.9%) |
| Idelalisib 150 mg BID INT | 6/22 (27.3%) | 11/21 (52.4%) | 16/21 (76.2%) |
| Event | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/47 | 6/27 | 0/21 |
| Acute kidney injuryRenal and urinary disorders | 0/47 | 4/27 | 0/21 |
| Covid-19Infections and infestations | 1/47 | 1/27 | 2/21 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/47 | 2/27 | 0/21 |
| PneumoniaInfections and infestations | 1/47 | 2/27 | 1/21 |
| ColitisGastrointestinal disorders | 3/47 | 0/27 | 0/21 |
| AnaemiaBlood and lymphatic system disorders | 2/47 | 0/27 | 1/21 |
| PyrexiaGeneral disorders | 1/47 | 0/27 | 1/21 |
| Abdominal infectionInfections and infestations | 0/47 | 0/27 | 1/21 |
| Covid-19 pneumoniaInfections and infestations | 1/47 | 0/27 | 1/21 |
| Event | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/47 | 12/27 | 6/21 |
| NeutropeniaBlood and lymphatic system disorders | 12/47 | 10/27 | 4/21 |
| RashSkin and subcutaneous tissue disorders | 11/47 | 4/27 | 6/21 |
| PyrexiaGeneral disorders | 11/47 | 6/27 | 3/21 |
| NauseaGastrointestinal disorders | 5/47 | 6/27 | 4/21 |
| Aspartate aminotransferase increasedInvestigations | 8/47 | 6/27 | 0/21 |
| AnaemiaBlood and lymphatic system disorders | 10/47 | 3/27 | 2/21 |
| Alanine aminotransferase increasedInvestigations | 9/47 | 5/27 | 0/21 |
| VomitingGastrointestinal disorders | 4/47 | 5/27 | 1/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/47 | 4/27 | 0/21 |
Safety analysis set included all participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 14 | 11 | 45 |
| >=65 years | 27 | 13 | 10 | 50 |
| Age, Continuous(years) | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT | Total |
|---|---|---|---|---|
| Mean | 65 ± 13.0 | 62 ± 13.6 | 63 ± 11.6 | 64 ± 12.8 |
| Sex: Female, Male(Participants) | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT | Total |
|---|---|---|---|---|
| Female | 23 | 13 | 8 | 44 |
| Male | 24 | 14 | 13 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 3 |
| Not Hispanic or Latino | 42 | 26 | 17 | 85 |
| Unknown or Not Reported | 4 | 1 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT | Total |
|---|---|---|---|---|
| Race — White | 42 | 25 | 18 | 85 |
| Race — Unknown or Not Reported | 4 | 1 | 2 | 7 |
| Race — Asian | 1 | 0 | 0 | 1 |
| Race — Black or African American | 0 | 0 | 1 | 1 |
| Race — Other or More Than One Race | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Idelalisib 150 mg BID | Idelalisib 100 mg BID | Idelalisib 150 mg BID INT | Total |
|---|---|---|---|---|
| Italy | 10 | 5 | 4 | 19 |
| Poland | 8 | 6 | 4 | 18 |
| Spain | 8 | 4 | 6 | 18 |
| United Kingdom | 6 | 5 | 4 | 15 |
| France | 5 | 2 | 2 | 9 |
| Czechia | 4 | 3 | 1 | 8 |
| Israel | 4 | 0 | 0 | 4 |
| Australia | 0 | 2 | 0 | 2 |
| Canada | 1 | 0 | 0 | 1 |
| Romania | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Jan 2016 to primary completion in Sep 2022, 80 months.
Results were first posted in Aug 2023, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib